PH12021550834A1 - 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament - Google Patents
4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicamentInfo
- Publication number
- PH12021550834A1 PH12021550834A1 PH12021550834A PH12021550834A PH12021550834A1 PH 12021550834 A1 PH12021550834 A1 PH 12021550834A1 PH 12021550834 A PH12021550834 A PH 12021550834A PH 12021550834 A PH12021550834 A PH 12021550834A PH 12021550834 A1 PH12021550834 A1 PH 12021550834A1
- Authority
- PH
- Philippines
- Prior art keywords
- pyrazin
- ylmethyl
- medicament
- morpholine derivatives
- ciation
- Prior art date
Links
- JKLJHSTZIZURSR-UHFFFAOYSA-N 4-(pyrazin-2-ylmethyl)morpholine Chemical class C=1N=CC=NC=1CN1CCOCC1 JKLJHSTZIZURSR-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 102000034527 Retinoid X Receptors Human genes 0.000 abstract 1
- 108010038912 Retinoid X Receptors Proteins 0.000 abstract 1
- 230000003281 allosteric effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18200943 | 2018-10-17 | ||
| PCT/EP2019/078027 WO2020079039A1 (en) | 2018-10-17 | 2019-10-16 | 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12021550834A1 true PH12021550834A1 (en) | 2021-10-04 |
Family
ID=63878518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12021550834A PH12021550834A1 (en) | 2018-10-17 | 2021-04-14 | 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US11166958B2 (he) |
| EP (1) | EP3867244B1 (he) |
| JP (1) | JP7093468B2 (he) |
| KR (1) | KR20210079325A (he) |
| CN (1) | CN112888685B (he) |
| AR (1) | AR116711A1 (he) |
| AU (1) | AU2019362330B2 (he) |
| BR (1) | BR112021004993A2 (he) |
| CA (1) | CA3113308A1 (he) |
| CL (1) | CL2021000858A1 (he) |
| CO (1) | CO2021004612A2 (he) |
| CR (1) | CR20210184A (he) |
| DK (1) | DK3867244T3 (he) |
| DO (1) | DOP2021000069A (he) |
| EA (1) | EA202191014A1 (he) |
| EC (1) | ECSP21027009A (he) |
| ES (1) | ES2940184T3 (he) |
| FI (1) | FI3867244T3 (he) |
| HR (1) | HRP20230249T1 (he) |
| HU (1) | HUE061891T2 (he) |
| IL (1) | IL282142B2 (he) |
| JO (1) | JOP20210075A1 (he) |
| LT (1) | LT3867244T (he) |
| MA (1) | MA53898B1 (he) |
| MX (1) | MX2021004418A (he) |
| PE (1) | PE20211278A1 (he) |
| PH (1) | PH12021550834A1 (he) |
| PL (1) | PL3867244T3 (he) |
| PT (1) | PT3867244T (he) |
| RS (1) | RS63988B1 (he) |
| SA (1) | SA521421756B1 (he) |
| SG (1) | SG11202103806VA (he) |
| SI (1) | SI3867244T1 (he) |
| TW (1) | TWI828779B (he) |
| UA (1) | UA128408C2 (he) |
| WO (1) | WO2020079039A1 (he) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202112378A (zh) * | 2019-06-04 | 2021-04-01 | 德商百靈佳殷格翰國際股份有限公司 | 嘌呤衍生物及其作為藥物之用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6495561B2 (en) | 1999-10-29 | 2002-12-17 | Merck & Co., Inc. | 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists |
| EP1390034A4 (en) | 2001-04-03 | 2005-07-13 | Merck & Co Inc | NMDA / NR2B NONARYL-HETEROCYCLO AMIDYL N-SUBSTITUTE ANTAGONISTS |
| EP1409477B1 (en) * | 2001-07-24 | 2008-09-17 | Richter Gedeon NYRT | Piperidine derivatives as nmda receptor antagonists |
| CA2630517A1 (en) * | 2005-12-06 | 2007-06-14 | Merck & Co., Inc. | Morpholine carboxamide prokineticin receptor antagonists |
| US20110319416A1 (en) * | 2009-01-28 | 2011-12-29 | Emory University | Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions |
| WO2012128582A2 (en) | 2011-03-23 | 2012-09-27 | Hyundai Pharm Co., Ltd. | A COMPOUND FOR INHIBITING HUMAN 11-β-HYDROXY STEROID DEHYDROGENASE TYPE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME |
| AU2013333988B2 (en) * | 2012-10-18 | 2017-03-09 | F. Hoffmann-La Roche Ag | Ethynyl derivatives as modulators of mGluR5 receptor activity |
| WO2015130905A1 (en) | 2014-02-27 | 2015-09-03 | Merck Patent Gmbh | Heterocyclic compounds as nav channel inhibitors and uses thereof |
| WO2016029146A1 (en) | 2014-08-22 | 2016-02-25 | University Of Washington | Specific inhibitors of methionyl-trna synthetase |
| AU2016340239A1 (en) * | 2015-10-14 | 2018-05-31 | Bristol-Myers Squibb Company | Selective NR2B antagonists |
-
2019
- 2019-10-16 KR KR1020217014924A patent/KR20210079325A/ko not_active Application Discontinuation
- 2019-10-16 CA CA3113308A patent/CA3113308A1/en active Pending
- 2019-10-16 TW TW108137247A patent/TWI828779B/zh active
- 2019-10-16 IL IL282142A patent/IL282142B2/he unknown
- 2019-10-16 RS RS20230140A patent/RS63988B1/sr unknown
- 2019-10-16 HR HRP20230249TT patent/HRP20230249T1/hr unknown
- 2019-10-16 BR BR112021004993-2A patent/BR112021004993A2/pt unknown
- 2019-10-16 WO PCT/EP2019/078027 patent/WO2020079039A1/en active Application Filing
- 2019-10-16 CR CR20210184A patent/CR20210184A/es unknown
- 2019-10-16 MA MA53898A patent/MA53898B1/fr unknown
- 2019-10-16 SG SG11202103806VA patent/SG11202103806VA/en unknown
- 2019-10-16 SI SI201930465T patent/SI3867244T1/sl unknown
- 2019-10-16 JO JOP/2021/0075A patent/JOP20210075A1/ar unknown
- 2019-10-16 PE PE2021000513A patent/PE20211278A1/es unknown
- 2019-10-16 EA EA202191014A patent/EA202191014A1/ru unknown
- 2019-10-16 AU AU2019362330A patent/AU2019362330B2/en active Active
- 2019-10-16 ES ES19786343T patent/ES2940184T3/es active Active
- 2019-10-16 AR ARP190102937A patent/AR116711A1/es unknown
- 2019-10-16 CN CN201980067936.7A patent/CN112888685B/zh active Active
- 2019-10-16 HU HUE19786343A patent/HUE061891T2/hu unknown
- 2019-10-16 PT PT197863434T patent/PT3867244T/pt unknown
- 2019-10-16 PL PL19786343.4T patent/PL3867244T3/pl unknown
- 2019-10-16 JP JP2021520981A patent/JP7093468B2/ja active Active
- 2019-10-16 MX MX2021004418A patent/MX2021004418A/es unknown
- 2019-10-16 US US16/654,030 patent/US11166958B2/en active Active
- 2019-10-16 FI FIEP19786343.4T patent/FI3867244T3/fi active
- 2019-10-16 LT LTEPPCT/EP2019/078027T patent/LT3867244T/lt unknown
- 2019-10-16 EP EP19786343.4A patent/EP3867244B1/en active Active
- 2019-10-16 DK DK19786343.4T patent/DK3867244T3/da active
- 2019-10-16 UA UAA202102481A patent/UA128408C2/uk unknown
-
2021
- 2021-04-07 CL CL2021000858A patent/CL2021000858A1/es unknown
- 2021-04-13 CO CONC2021/0004612A patent/CO2021004612A2/es unknown
- 2021-04-14 SA SA521421756A patent/SA521421756B1/ar unknown
- 2021-04-14 PH PH12021550834A patent/PH12021550834A1/en unknown
- 2021-04-16 EC ECSENADI202127009A patent/ECSP21027009A/es unknown
- 2021-04-16 DO DO2021000069A patent/DOP2021000069A/es unknown
- 2021-08-27 US US17/458,631 patent/US20210393644A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021006421A (es) | Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17). | |
| PH12016502081A1 (en) | Compounds for treating spinal muscular atrophy | |
| MX2018005890A (es) | Composiciones para tratar atrofia muscular espinal. | |
| MX2022013612A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas. | |
| MX368387B (es) | A22k, desb27, b29r, des b30 en la posicion epsilon del analogo de insulina humana acilada de lisina 22. | |
| MX2023014492A (es) | Compuestos utiles en la terapia para el vih. | |
| MX2018002223A (es) | Derivados de insulina novedosos y usos medicos de los mismos. | |
| CR20220215A (es) | Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1 | |
| CR20220216A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1 | |
| ZA201805358B (en) | 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives | |
| SA520412155B1 (ar) | مشتقات إيميدازوبيريدين واستخدامها كدواء | |
| PH12020550050A1 (en) | Novel acylated insulin analogues and uses thereof | |
| PH12015502128A1 (en) | Novel dosing regimens of celgosivir for the treatment of dengue | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| PH12021550834A1 (en) | 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament | |
| MX2019009909A (es) | Composiciones farmaceuticas para terapia de combinacion. | |
| MX2018012952A (es) | Composicion oftalmica que comprende una combinacion sinergica de glucogeno y acido hialuronico o sal del mismo. | |
| MX2015012575A (es) | Novedosos derivados de acrilamida como agentes contra la malaria. |